Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019-2020 US Influenza Season.

Mahrukh ImranCarrie W MillsKimberly W McDermottAlex DeanAlina BogdanovIan McGovernMendel D M Haag

Published in: Open forum infectious diseases (2024)

This study demonstrated comparable effectiveness of aTIV and HD-TIV among individuals with no identified risk factors and higher effectiveness of aTIV compared with HD-TIV in preventing any IRMEs, outpatient IRMEs, and influenza- or pneumonia-related hospitalizations among those with at least 1 or multiple high-risk factors in adults ≥65 years old.

Keyphrases

risk factors
randomized controlled trial
high dose
systematic review
physical activity
intensive care unit
stem cell transplantation
middle aged
community dwelling
mechanical ventilation
respiratory failure